CochLear (OTCMKTS:CHEOY) Stock Price Up 5% – Here’s What Happened

Shares of CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) rose 5% on Tuesday. The company traded as high as $46.89 and last traded at $46.89. Approximately 336 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 50,134 shares. The stock had previously closed at $44.64.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group downgraded shares of CochLear from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 18th. Royal Bank Of Canada lowered shares of CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 target price on the stock. in a report on Thursday, July 16th. Zacks Research raised shares of CochLear from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd. Finally, Jefferies Financial Group downgraded shares of CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $117.00.

CochLear Price Performance

The business has a 50-day simple moving average of $47.63 and a 200-day simple moving average of $44.61.

CochLear Company Profile

Cochlear Limited is an Australian medical technology company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its products are designed to help restore access to sound for individuals who may not benefit sufficiently from conventional hearing aids.

The company’s product portfolio includes cochlear implants, sound processors, bone-conduction hearing implants and related accessories and services. Cochlear also provides professional support, rehabilitation resources and connectivity solutions for recipients, hearing-health specialists and caregivers.

Founded in 1981 and headquartered in Sydney, Australia, Cochlear traces its origins to research led by Professor Graeme Clark, whose work contributed to the development of the world’s first multichannel cochlear implant.